TP53 and endometrioid adenocarcinoma: Among them, the positive rates were 27.3% in G1 (3/11), 31.3% in G2 (5/16), and 38.5% in G3 (5/13), indicating that TP53 gene mutations were not significantly correlated with the histological grade in endometrioid carcinoma.